JAK inhibitors in Phmyeloproliferative
|
|
- Mercy Carroll
- 5 years ago
- Views:
Transcription
1 Disclosures for A Pardanani Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board TargeGen, Cytopia/YM BioSciences, PharmaMar None None None None None Presentation includes discussion of the following off-label use of a drug or medical device. Hydroxyurea, interferon-alpha, imatinib mesylate, 2-CdA, busulfan, anagrelide, thalidomide, lenalidomide, pomalidomide, prednisone, androgens, erythropoiesis stimulating agents, alemtuzumab, INCB18424, TG11348, CYT387, RAD1, PKC412, Panobinostat, Givinostat JAK inhibitors in Phmyeloproliferative neoplasms: survival benefit or palliation? A. Pardanani, MBBS, PhD Mayo Clinic 1
2 "If you believe that, I've got a bridge to sell you." brooklyn bridge Chronic phase Accel./blast phase JAK2, MPL, TET2, ASXL1, CBL, IDH1/2, IKZF4, LNK, EZH2, DNMT3A?? Disease-initiatinginitiating mutations Phenotype-modifying mutations Disease-transforming mutations Polyclonal stem cells harboring disease-susceptibilitysusceptibility alleles such as JAK2 46/1 haplotype? BCR-ABL1 negative MPN BCR-ABL1 * * * * * * * * * * * * ** * * PV ET PMF?? * * * * * * * * * JAK2(-) AML JAK2(+) AML? Tefferi A. Leukemia 24: , 21 CML Blast phase CML 2
3 Mutations galore in BCR-ABL1-negative myeloid neoplasms MPL JAK2 LNK CBL PV ET PMF CMML RARS-T MDS AML IDH TET2 EZH2 IKZF1 ASXL1 A. Figure 1 Wild-Type Clonal hierarchy in a patient with PMF and two distinct LNK mutations, JAK2V617F and IDH2 R14Q C. LNK _delGGCCCCG wild-type LNK 955_delA heterozygous LNK 955_delA IDH2 R14Q LNK _del GGCCCCG JAK2 V617F heterozygous homozygous JAK2 V617F wild-type IDH2 R14Q wild-type heterozygous heterozygous B. Wild-Type LNK _del GGCCCCG Wild-Type LNK _del GGCCCCG LNK _del GGCCCCG Homozygous LNK _del GGCCCCG Homozygous LNK _del GGCCCCG LNK 955_delA LNK 955_delA LNK 955_delA LNK 955_delA LNK 955_delA Wild-Type JAK2 V617F Wild-Type IDH2 R14Q n=1 5% Wild-Type JAK2 V617F IDH2 R14Q n=3 15% JAK2 V617F IDH2 R14Q n=4 2% Wild-Type JAK2 V617F IDH2 R14Q n=7 35% JAK2 V617F IDH2 R14Q n=7 35% LNK Mutation Studies In Chronic- and Blast-Phase Myeloproliferative Neoplasms and JAK2 Mutation-Negative Erythrocytosis ASH 21, abstract #415 3
4 Targeted therapy in MPN What mutant molecule should we target? MPL <1% LNK <3% CBL <3% JAK2 >95% IDH <5% TET2 <2% EZH2 <5% IKZF1 <1% ASXL1 <1% DIPSS-plus (Dynamic International Prognostic Scoring System + karyotype + platelet count + transfusion status) risk stratification in 793 patients with primary myelofibrosis seen at Mayo Clinic Rochester Survival Low risk ( adverse points) n=66; median survival ~ 185 months Intermediate-1 risk (1 adverse point) n=174; median survival ~ 78 months Intermediate-2 risk (2 or 3 adverse points) n=36; median survival ~ 35 months High risk (4 or more adverse points) n=193; median survival ~ 16 months P<.1 Adverse points 1. Hgb < 1 g/dl 2. Circulating blasts 1% 3. WBC > 25k 4. Constitutional symptoms 5. Age > 65 years 6. Transfusion need 7. Platelets < 1k 8. Unfavorable karyotype IPSS/DIPSS DIPSS-plus Monosomal karyotype Complex karyotype Trisomy 8-7/del(7q) Del(5q) Inv(3) isochromosome 17q/17p- 12p- 11q23 abnormality Gangat et al. ASH 21 abstract #414 Months Gangat et al., J Clin Oncol. 211 Feb 1;29(4):
5 Primary end point for Phase III JAK inhibitor trials in myelofibrosis 35% decrease in spleen volume by MRI/CT OS PFS JAK inhibitor ATP mimetics in clinical trials for myelofibrosis Anti-JAK2 IC5 (JAK1/JAK3 selectivity) INCB nm (Phase 1/2 study) (x1./x98) N=153 TG nm (Phase 1/2 study) (x35/x332) N=59 CYT nm (Phase 1/2 study) (x.6/x8.6) N=6 CEP-71 1 nm (Phase 2 study) (x?/x3) SB1518 (Phase 1/2 study) AZD148 (Phase 1/2 study) LY (Phase 1/2 study) 22 nm (x58/x24).26 nm (x5/x15) Scant literature Non-JAK kinase targets None of ~28 kinases evaluated FLT3 RET JNK1 CDK2 FLT3 TrkA FLT3 TrkA Aurora A FGFR1 Scant literature 5
6 Safety and Efficacy of INCB18424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis JAK-1/JAK-2 Verstovsek S et al. N Engl J Med 21;363: % 49% INCB18424 Phase 1/2 study N=153 Median f/u=14.7 months DLT=Gr 3/4 thrombocytopenia MTD=25 mg BID or 1 mg QD Verstovsek S et al. N Engl J Med 21;363:
7 Study discontinuation rate=25% Verstovsek S et al. N Engl J Med 21;363: Longer-Term Follow up with TG11348 Therapy In Myelofibrosis Confirms Sustained Improvement In Splenomegaly, Disease-Related Symptoms, and JAK2V617F Allele Burden JAK-2 J Clin Oncol. 211 Mar 1;29(7):
8 39% 39% 47% 47% Cycle 6 Cycle 12 Early satiety 1 9 Night sweats 8 Percentage of Subjects TG Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle 6 Resolved From Mild Resolved From Moderate or Severe Phase 1 study N=59 Median f/u=38 days Normalization of Leukocyte count = 56% Normalization of platelet count = 88% DLT=Gr 3/4 elevated amylase/lipase MTD=68 mg QD Adverse Event Grade 1/2 All subjects N=59 TG11348: safety and tolerability Grade 3/4 study discontinuation rate = 44% MTD cohort N=4 Grade 1/2 Grade 3/4 Nausea 66% 3% 78% 5% Vomiting 54% 3% 68% 3% Diarrhea 6% % 1% % Lipase increased 17% 1% 23% 15% ALT increased 19% 7% 23% 8% AST increased 25% 2% 33% 3% Creatinine increased 24% % 28% % Alkaline phosphatase increased 17% % 23% % Subjects Number of MTD cohort: 7% required dose reduction Cycle 1 Cycle 2 Cycle 3 Cycle 4 Cycle 5 Cycle Anorexia 14% % 15% % Peripheral edema 1% % 1% % Skin exfoliation 14% % 2% % Adverse Event All N= Subjects 59 MTD N= Cohort 4 Grade 1/2 Grade 3/4 Grade 1/2 Grade 3/4 Anemia (N=37) 8% 35% 8% 54% Thrombocytopenia 17% 24% 2% 28% Neutropenia 63% 1% 5% 1% 8
9 A Phase I/II Study of CYT387, An Oral JAK-1/2 Inhibitor, In Myelofibrosis: Significant Response Rates In Anemia, Splenomegaly, and Constitutional Symptoms ASH 21, Abstract #46 JAK-1/JAK % All 1mg/d 15mg/d 2mg/d 3mg/d 4mg/d subjects (n=3) (n=19) (n=3) (n=24) (n=4) (n=53) Spleen response (IWG) Night sweats (n=26) Bone Pruritus pain (n=13) (n=25) Fever (n=5) All 15 mg/d 3 mg/d 1 CYT387 Phase 1/2 study N=6 Median f/u 4.9 months %/43% 58%/69% Anemia evaluable Transfusion-dep DLT Gr 3 elevated lipase/headache MTD 3 mg QD mg/d (n=2/1) 15mg/d (n=17/14) 3mg/d (n=19/16) 4mg/d (n=4/2) 9
10 CYT387: safety and tolerability study discontinuation rate = 5% Adverse events Grade 1 Grade 2 Grade 3 Grade 4 Nausea 15% Diarrhea 12% Abdominal pain 7% Vomiting 3% Increased transaminases 2% 3% Increased bilirubin 16% Increased lipase 7% 5% Increased amylase 5% 5% Increased Alk Pase 7% 3% Increased creatinine 5% All patients (n=6) Starting dose 15 mg/day Starting dose 3 mg/day Transient Lightheadedness Systolic BP decrease >2 mm Hg 43% 52% 19% 33% 59% 63% Numbness 5% Headache 1% 3% Prolonged QTc 3% Dry mouth 3% Adverse events Grades 1/2 Grade 3 Grade 4 Anemia 7% 7% Thrombocytopenia 42% 18% 8% Neutropenia 2% 5% Platelet inclusion criteria: INCB18424: 1k ; TG11348: 5K; CYT387: 5k The two pathogenetic faces of myelofibrosis Secondary inflammatory state (cytokine-mediated) JAK-STAT-driven clonal myeloproliferation Abnormal cytokine milieu Bone marrow stromal reaction AML Survival Leukocytosis Thrombocytosis Ineffective hematopoiesis (anemia) Extramedullary hematopoiesis (splenomegaly) Hypercatabolic symptoms, pruritus and cachexia 1
11 Units JAK2V617F allele burden C1D1 C7D1 C13D Interleukin-6 Absolute Change (pg/ml) TNF-α 5 5 Baseline Cycle 6 Cycle 12 6% 31% 32% (23-1%) (4-1%) (7-1%) p <.1 Absolute Change (pg/ml) Interleukin-8 Absolute Change (pg/ml) Interleukin-2 TG11348 JAK1 JAK1/2 JAK2 JAK2V617F J Clin Oncol. 211 Mar 1;29(7): Verstovsek S et al. N Engl J Med 21;363:1117 INCB18424 JAK1 JAK1/2 JAK2 JAK2V617F Verstovsek S et al. N Engl J Med 21;363:
12 Can targeting cytokines favorably impact survival in MF? Plasma cytokines in primary myelofibrosis are abnormally increased and correlate with phenotype and prognosis IL-8, IL-2R, IL-12, IL-15 and CXCL1 were independently associated with poor survival 1 9 treatment-naive patients with PMF Plasma IL-8 and IL-2R in the normal range (n=6) Median survival ~8 months One or both cytokines elevated (n=3) Median survival ~17 months Only intermediate-1 risk patients considered; N = 27 Plasma IL-8 and IL-2R in the normal range (n=21) Median survival not reached One or both cytokines elevated (n=6) Median survival ~17 months val Surviv P< Months J Clin Oncol. 211 Apr 1;29(1):
13 The fallacy of retrospective comparisons Mature survival data for 288 young patients (age 65 years) with primary myelofibrosis stratified by year of diagnosis P=.3 Years N= Years N=127 Before 199 N= Updated data from Vaidya et al. Mayo Clin Proc 29;84:
14 What can we expect from JAK inhibitor therapy in PV or ET? Survival and risk of leukemic transformation in ET are significantly influenced by accurate morphologic diagnosis: An international study of 1,14 patients. Barbui et al. Blood 21; 21 ASH abstract #457 ET and pre-fibrotic MF vs Europe* Age- and sex-adjusted actuarial survival curves 1,9,8,7 Survival,6,5 4,4,3,2 Europe ET Pre-fibrotic MF, Years Fibrotic progression was significantly less in the presence of JAK2V617F 14
15 What is the prognosis for JAK inhibitors in Ph- myeloproliferative neoplasms? Myelofibrosis Well tolerated, significant palliation Disease modifying? Combination with other agents Polycythemia vera / Essential thrombocythemia limited niche (eg. refractory pruritus) Unproven benefit wrt clinically relevant end points 15
Presenter Disclosure Information
Welcome to Master Class for Oncologists Session 3: 2: PM 3:3 PM Pasadena, CA May 1, 21 Myeloproliferative Neoplasms 21 Speaker: Ayalew Tefferi Mayo Clinic, Rochester, MN Presenter Disclosure Information
More informationWelcome to Master Class for Oncologists. Session 3: 9:15 AM - 10:00 AM
Welcome to Master Class for Oncologists Session 3: 9:15 AM - 10:00 AM Miami, FL December 18, 2009 Myeloproliferative Neoplasms: Bringing Order to Complexity and Achieving Optimal Outcomes Speaker: Andrew
More informationMayo Clinic Treatment Strategy in Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis 2013 Update
Mayo Clinic Treatment Strategy in Essential Thrombocythemia, Polycythemia Vera and Myelofibrosis 2013 Update Ayalew Tefferi Mayo Clinic, Rochester, MN 0 20 40 60 80 100 Percent Survival in 337 Mayo Clinic
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More informationJAK2 Inhibitors for Myeloproliferative Diseases
JAK2 Inhibitors for Myeloproliferative Diseases Srdan (Serge) Verstovsek M.D., Ph.D. Associate Professor Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA Myeloproliferative
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More informationMPNs: JAK2 inhibitors & beyond. Mohamed Abdelmooti (MD) NCI, Cairo University, Egypt
MPNs: JAK2 inhibitors & beyond Mohamed Abdelmooti (MD) NCI, Cairo University, Egypt Myeloproliferative Neoplasms (MPNs) AGENDA: 1. Molecular biology 2. New WHO diagnostic criteria. 3. Risk stratification
More informationCLINICAL POLICY DEPARTMENT: Medical Management DOCUMENT NAME: JakafiTM REFERENCE NUMBER: NH.PHAR.98
PAGE: 1 of 6 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationClassical Ph-1neg myeloproliferative neoplasms: Ruxolitinib in myelofibrosis. Francesco Passamonti Università degli Studi dell Insubria, Varese
Classical Ph-1neg myeloproliferative neoplasms: Ruxolitinib in myelofibrosis Francesco Passamonti Università degli Studi dell Insubria, Varese DIPSS during f-up IPSS at diagnosis Diagnose MF and genotype
More informationShould Intermediate-I risk PMF be transplanted immediately or later? Position: Later
Should Intermediate-I risk PMF be transplanted immediately or later? Position: Later Vikas Gupta, MD, FRCP, FRCPath Associate Professor Department of Medicine Leukemia/BMT Programs Princess Margaret Cancer
More informationChi sono i candidati agli inibitori di JAK2
Chi sono i candidati agli inibitori di JAK2 Francesco Passamon, Hematology, University Hospital Varese, Italy Ruxoli8nib (US approved in MF; EAP study and compassionate use in Italy) SAR302503 (phase 3
More informationDisclosures for Ayalew Tefferi
Disclosures for Ayalew Tefferi Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Janssen, Geron, Celgene, Sanofi-Aventis, Gilead Sciences, Incyte
More informationStifel Nicolaus 2013 Healthcare Conference. John Scarlett, M.D. Chief Executive Officer September 11, 2013
Stifel Nicolaus 2013 Healthcare Conference John Scarlett, M.D. Chief Executive Officer September 11, 2013 1 forward-looking statements Except for the historical information contained herein, this presentation
More informationIntro alla patologia. Giovanni Barosi. Fondazione IRCCS Policlinico San Matteo Pavia
Settima Giornata Fiorentina dedicata ai pazienti con malattie mieloproliferative croniche Sabato 13 Maggio 2017 CRIMM Centro di Ricerca e Innovazione per le Malattie Mieloproliferative AOU Careggi Intro
More informationDisclosures for Angela Fleischman
Disclosures for Angela Fleischman Principal investigator role Employee Consultant Major Stockholder Speakers Bureau Scientific Advisory Board Sierra, Incyte None None None Incyte None Presentation includes
More informationNew Therapies for MPNs
Pomalidomide and IMIDS in Myelofibrosis New Therapies for MPNs Fourth International Workshop on CML and MPN Natchez Louisiana Ruben A. Mesa, MD Professor of Medicine Mayo Clinic College of Medicine Director
More informationJAKAFI (ruxolitinib phosphate) oral tablet
JAKAFI (ruxolitinib phosphate) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationOpportunities for Optimal Testing in the Myeloproliferative Neoplasms. Curtis A. Hanson, MD
Opportunities for Optimal Testing in the Myeloproliferative Neoplasms Curtis A. Hanson, MD 2013 MFMER slide-1 DISCLOSURES: Relevant Financial Relationship(s) None Off Label Usage None 2013 MFMER slide-2
More informationCurrent Prognostication in Primary Myelofibrosis
Current Prognostication in Primary Myelofibrosis Francisco Cervantes Hematology Department, Hospital Clínic, Barcelona, Spain Florence, April 2011 Survival in PMF No. patients: 1,054 Median Srv (95% CI):
More informationPractical Considerations in the Treatment Myeloproliferative Neoplasms: Prognostication and Current Treatment Indy Hematology
Practical Considerations in the Treatment Myeloproliferative Neoplasms: Prognostication and Current Treatment Indy Hematology Angela Fleischman MD PhD UC Irvine March 9, 2019 Disclosures: Angela Fleischman
More informationLeukemia and subsequent solid tumors among patients with myeloproliferative neoplasms
Leukemia and subsequent solid tumors among patients with myeloproliferative neoplasms Tiziano Barbui (tbarbui@asst-pg23.it Hematology and Research Foundation,Ospedale Papa Giovanni XXIII, Bergamo Italy
More informationWhat are myeloproliferative neoplasms??
Welcome to Master Class for Oncologists Session 3: 2:45 PM - 3:30 PM New York, NY October 24, 2008 Myeloproliferative Neoplasms Speaker: Ayalew Tefferi, MD Professor of Medicine, Mayo Clinic, Rochester,
More informationJ Clin Oncol 29: by American Society of Clinical Oncology INTRODUCTION
VOLUME 29 NUMBER 4 FEBRUARY 1 11 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T DIPSS Plus: A Refined Dynamic International Prognostic Scoring System for Primary Myelofibrosis That Incorporates
More informationHow I Treat Myelofibrosis. Adam Mead, MD, PhD University of Oxford Oxford, United Kingdom
How I Treat Myelofibrosis Adam Mead, MD, PhD University of Oxford Oxford, United Kingdom Primary Myelofibrosis Archiv Fur Pathol. 1879;78:475-96. 2 cases of leukemia with peculiar blood and marrow findings
More informationTransplants for MPD and MDS
Transplants for MPD and MDS The question is really who to transplant, with what and when. Focus on myelofibrosis Jeff Szer Royal Melbourne Hospital Myelodysplasia Little needs to be said Despite new therapies
More informationManaging ET in Tiziano Barbui MD
Managing ET in 2019 Tiziano Barbui MD (tbarbui@asst-pg23.it) Hematology and Foundation for Clinical Research, Hospital Papa Giovanni XXIII Bergamo, Italy Managing ET in 2019 Establish diagnosis Risk Stratification
More informationASH 2013 Analyst & Investor Event
ASH 2013 Analyst & Investor Event December 9, 2013 John A. Scarlett, MD President & CEO Forward-Looking Statements Except for the historical information contained herein, this presentation contains forward-looking
More informationCME Information: Primary myelofibrosis: 2017 update on diagnosis, risk-stratification and management
CME ARTICLE AJH CME Information: Primary myelofibrosis: 2017 update on diagnosis, risk-stratification and management CME Editor: Ayalew Tefferi, M.D. Author: Ayalew Tefferi, M.D. If you wish to receive
More informationPolycytemia Vera, Essential Thrombocythemia and Myelofibrosis: prognosis and treatment
Polycytemia Vera, Essential Thrombocythemia and Myelofibrosis: prognosis and treatment BHS Training course 2013-2015 Timothy Devos POLYCYTEMIA VERA PV: clinical manifestations thrombosis (art > ven) facial
More informationPrimary myelofibrosis (PMF) is a hematologic malignancy
Brief Report Mature Survival Data for 176 Patients Younger Than With Primary Myelofibrosis Diagnosed Between 1976 and 5: Evidence for Survival Gains in Recent Rakhee Vaidya, MBBS; Sergio Siragusa, MD;
More informationWHO Update to Myeloproliferative Neoplasms
WHO Update to Myeloproliferative Neoplasms Archana M Agarwal, MD, Associate Professor of Pathology University of Utah Department of Pathology/ARUP Laboratories Myeloproliferative Neoplasms The categories
More informationPolycythemia Vera and other Myeloproliferative Neoplasms. A.Mousavi
Polycythemia Vera and other Myeloproliferative Neoplasms A.Mousavi Chronic MPNs Multipotent hematopoietic progenitor cell is origin. Overproduction of one or more formed element of blood cells without
More informationHeme 9 Myeloid neoplasms
Heme 9 Myeloid neoplasms The minimum number of blasts to diagnose acute myeloid leukemia is 5% 10% 20% 50% 80% AML with the best prognosis is AML with recurrent cytogenetic abnormality AML with myelodysplasia
More informationPrognostic models in PV and ET
Prognostic models in PV and ET Francesco Passamonti Hematology, Varese, Italy Current risk stratification in PV and ET: statement from European LeukemiaNet consensus Age over 60 years Previuos thrombosis
More informationHow to monitor MPN patients
How to monitor MPN patients MPN carries significant burden and risk Transformation to MF or AML 1 Neurological complications 2 MPN-associated general symptoms (eg, pruritus, fatigue) 3 Microvascular symptoms
More information[COMPREHENSIVE GENETIC ASSAY PANEL ON
2014 SN GENELAB AND RESEARCH CENTER DR. SALIL VANIAWALA, PH.D [COMPREHENSIVE GENETIC ASSAY PANEL ON MYELOPROLIFERATIVE NEOPLASMS] SN Genelab presents one of the most comprehensive genetic assay panel for
More informationLondon Cancer. Myelofibrosis guidelines. August Review August Version v1.0. Page 1 of 12
London Cancer Myelofibrosis guidelines August 2013 Review August 2013 Version v1.0 Page 1 of 12 CONTENTS 1. DIAGNOSIS... 3 1a. BCSH (2012)... 3 1b. WHO (2009) diagnostic criteria for PMF:... 4 2. MOLECULAR
More informationShould Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!!
Should Mutational Status in Primary Myelofibrosis (PMF) Guide Therapy..YES!!! Lindsay Anne Magura Rein, MD Division of Hematologic Malignancies and Cellular Therapy/BMT A Little Bit of History.. 1665 Advanced
More informationPost-ASH 2015 CML - MPN
Post-ASH 2015 CML - MPN Fleur Samantha Benghiat, MD, PhD Hôpital Erasme, Brussels 09.01.2016 1. CML CML 1st line ttt Prognosis Imatinib Nilotinib Response Discontinuation Dasatinib Low RISK PROFILE High
More informationJeanne Palmer, MD Mayo Clinic, Arizona
Setting the stage for Transplant in MPN Jeanne Palmer, MD Mayo Clinic, Arizona What will be covered What is a bone marrow transplant? When to start thinking about bone marrow transplant Timing of transplant
More informationShould Mutation Status in PMF Guide Therapy? No! Brady L. Stein, MD MHS Assistant Professor of Medicine Division of Hematology/Oncology
Should Mutation Status in PMF Guide Therapy? No! Brady L. Stein, MD MHS Assistant Professor of Medicine Division of Hematology/Oncology Case presentation A 67 yo woman presents to transition care, as her
More informationWhat is New in Leukemia & MPN in 2011?
Leukemia Update What Did We Learn from ASCO 211? Jorge Cortes, MD Department of Leukemia MD Anderson Cancer Center Houston, Texas What is New in Leukemia & MPN in 211? Cool things happening in MPN The
More informationMielofibrosi: inquadramento dei fattori prognostici
Mielofibrosi: inquadramento dei fattori prognostici Francesco Passamon, Division of Hematology University Hospital, Fondazione Macchi Varese, Italy Reduced survival in PMF and causes of death Median OS
More informationASBMT MDS/MPN Update Sunil Abhyankar, MD
ASBMT MDS/MPN Update Sunil Abhyankar, MD Professor of Medicine Medical Director, Pheresis and Cell Processing Division of Hematologic Malignancies and Cellular Therapeutics Department of Internal Medicine
More informationBiologia molecolare delle malattie mieloproliferative croniche Ph1-negative tipiche
41 CONGRESSO NAZIONALE SIE Bologna 14-17 Ottobre 2007 Biologia molecolare delle malattie mieloproliferative croniche Ph1-negative tipiche Alessandro M. Vannucchi Dip.. di Ematologia, Università degli Studi
More informationPreliminary Results From a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis
Preliminary Results From a Phase I Dose Escalation Trial of Ruxolitinib and the PI3Kδ Inhibitor TGR-1202 in Myelofibrosis Tamara K. Moyo, Andrew Sochacki, Gregory D. Ayers, Michael T. Byrne, Stephen A.
More informationCME Information: Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification, and management
AJH CME Information: Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification, and management Author: Ayalew Tefferi If you wish to receive credit for this activity,
More informationSponsor / Company: Sanofi Drug substance(s): SAR302503
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationDisclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms
Disclosure BCR/ABL1-Negative Classical Myeloproliferative Neoplasms Sonam Prakash declares affiliation with Incyte Corporation: Advisor for Hematopathology Publications Steering Committee Sonam Prakash,
More informationGenetic analysis and preclinical modeling of leukemic transformation of myeloproliferative neoplasms: Implications for therapeutic strategies
Genetic analysis and preclinical modeling of leukemic transformation of myeloproliferative neoplasms: Implications for therapeutic strategies Raajit Rampal, MD, PhD Assistant Attending Physician Leukemia
More informationWinship Cancer Institute of Emory University New Determinants and Approaches for MPN
Winship Cancer Institute of Emory University New Determinants and Approaches for MPN Elliott F. Winton August 8, 2014 Sea Island, Georgia Outline: MPN Determinants, Approaches Diagnosis Prognosis Treatment
More informationVirtually every intracellular signal transduction
MYELOPROLIFERATIVE DISORDERS Therapeutic potential of JAK2 inhibitors Srdan Verstovsek 1 1 The University of Texas M. D. Anderson Cancer Center, Houston, TX The discovery of an activating tyrosine kinase
More informationTechnical Bulletin No. 100
CPAL Central Pennsylvania Alliance Laboratory Technical Bulletin No. 100 August 2, 2012 JAK2 AND MPL 515 MUTATIONAL ANALYSIS Contact: Dr. Jeffrey Wisotzkey, 717-851-1422 Technical Director, CPAL Jill A.
More informationHow I treat high risk myeloproliferative neoplasms. Francesco Passamonti Università dell Insubria Varese - Italy
How I treat high risk myeloproliferative neoplasms Francesco Passamonti Università dell Insubria Varese - Italy How I treat high risk MF MF Treatment ELN 2018 Guidelines Anemia (Hb < 10 g/dl) Splenomegaly
More informationBack to the future in MPN. Claire Harrison Guy s and St Thomas Hospital NHS Foundation Trust, London, UK
Back to the future in MPN Claire Harrison Guy s and St Thomas Hospital NHS Foundation Trust, London, UK Primary Myelofibrosis 1879: Gustav Heuck (1854-1940) Archiv Fur Pathol 1879;78:475-96. 2 cases of
More informationClinical trials with JAK inhibitors for essential thrombocythemia and polycythemia vera
Clinical trials with JAK inhibitors for essential thrombocythemia and polycythemia vera Alessandro M. Vannucchi, MD Laboratorio Congiunto MMPC Department of Experimental and Clinical Medicine University
More informationWhat is next: Emerging JAK2 inhibitor combination studies. Alessandro M. Vannucchi. Section of Hematology, University of Florence, Italy
ymposium JAK2 Inhibition in Myelofibrosis: What Can We Expect in the Clinic? 4 5 May 2012 Lisbon, Portugal What is next: Emerging JAK2 inhibitor combination studies Alessandro M. Vannucchi ection of Hematology,
More informationMolecular aberrations in MPN. and use in the clinic. Timothy Devos MD PhD
Molecular aberrations in MPN and use in the clinic Timothy Devos MD PhD MB&C2017 24-3-2017 Introduction 1951: William Dameshek MPD MPN = clonal, hematopoietic stem cell disorders, proliferation in BM of
More informationJeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ
Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ What is acute leukemia? Cancer of the white blood cells Acute leukemia- Acute myelogenous leukemia Acute myeloid leukemia Myelofibrosis- Blast phase
More informationNon-commercial use only
Oncology Reviews 2012; volume 6:e13 Janus kinase inhibitors: jackpot or potluck? Keechilat Pavithran, Shripad Brahmanand Pande Department of Medical Oncology and Hematology, Amrita Institute of Medical
More informationCharacterization of MPL-mutated myeloid neoplasms: a review of 224 MPL+ cases
Article Characterization of MPL-mutated myeloid neoplasms: a review of 224 MPL+ cases Keming Lin 1,*, Gang Xu 1, Jie-Gen Jiang 1, Mayuko Imai 1, Zhao Wu 1, Paris Petersen 1, Kim Janatpour 1, and Bashar
More informationMPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs
MPN What's new in the morphological classification, grading of fibrosis and the impact of novel drugs Hans Michael Kvasnicka University of Frankfurt, Germany hans-michael.kvasnicka@kgu.de Disclosure of
More informationMyeloproliferative Disorders - D Savage - 9 Jan 2002
Disease Usual phenotype acute leukemia precursor chronic leukemia low grade lymphoma myeloma differentiated Total WBC > 60 leukemoid reaction acute leukemia Blast Pro Myel Meta Band Seg Lymph 0 0 0 2
More informationA. ILEA 1* A. M. VLADAREANU 2 E. NICULESCU-MIZIL 3
Bulletin of the Transilvania University of Braşov Series VI: Medical Sciences Vol. 9 (58) No. 1-2016 THE SIMULTANEOUS OCCURRENCE OF THE BCR-ABL TRANSLOCATION AND THE Jak2V617F MUTATION. DETECTION AND DYNAMICS
More information5/21/2018. Disclosures. Objectives. Normal blood cells production. Bone marrow failure syndromes. Story of DNA
AML: Understanding your diagnosis and current and emerging treatments Nothing to disclose. Disclosures Mohammad Abu Zaid, MD Assistant Professor of Medicine Indiana University School of Medicine Indiana
More informationUnmet Medical Needs in Myelofibrosis
Unmet Medical Needs in Myelofibrosis October 17, 2018 Safe Harbor Statement Except for statements of historical fact, any information contained in this presentation may be a forward-looking statement that
More informationThe Evolving Role of Transplantation for MPN
The Evolving Role of Transplantation for MPN (PMF, PV, ET) H.Joachim Deeg MD Fred Hutchinson Cancer Research Center, University of Washington, Seattle WA, SCCA jdeeg@fhcrc.org 10 th J. Niblack Conference
More informationCHALLENGING CASES PRESENTATION
CHALLENGING CASES PRESENTATION Michael C. Wiemann, MD, FACP Program Co-Chair and Vice President Indy Hematology Education President, Clinical St. John Providence Physician Network Detroit, Michigan 36
More informationEvolving Management of Myelofibrosis
Evolving Management of Myelofibrosis Srdan (Serge) Verstovsek M.D., Ph.D. Professor of Medicine Department of Leukemia University of Texas MD Anderson Cancer Center Houston, Texas, USA Why do we prognosticate?
More informationRESPONSE (NCT )
Changes in Quality of Life and Disease-Related Symptoms in Patients With Polycythemia Vera Receiving Ruxolitinib or Best Available Therapy: RESPONSE Trial Results Abstract #709 Mesa R, Verstovsek S, Kiladjian
More informationPolycthemia Vera (Rubra)
Polycthemia Vera (Rubra) Polycthemia Vera (Rubra) Increased red cells Clonal Myeloid lineages also increased 2-13 cases per million Mean age: 60 years Sites of Involvement Bone marrow Peripheral blood
More informationMyeloid neoplasms. Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories:
Myeloid neoplasms Note: Early arrest in the blast cell or immature cell "we call it acute leukemia" Myoid neoplasm divided in to 3 major categories: 1. AML : Acute myeloid leukemia(stem cell with myeloid
More informationJohn L Frater, MD Jeffery M Klco, MD, PhD Department of Pathology and Immunology Washington University School of Medicine St Louis, Missouri
Myeloproliferative Neoplasms: New Approaches to Diagnosis and Disease Monitoring John L Frater, MD Jeffery M Klco, MD, PhD Department of Pathology and Immunology Washington University School of Medicine
More informationDisclosure: Objectives/Outline. Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations. Nothing to disclose.
RC1 Leukemia: Genealogy of Pathology Practice: Old Diseases New Expectations RC2 Disclosure: Nothing to disclose Henry Moon Lecture: UCSF Annual Conference Kathryn Foucar, MD kfoucar@salud.unm.edu May
More informationSUPPLEMENTARY INFORMATION
Supplementary Information S1 Frequency of DNMT3A mutations in hematologic disorders and their associated clinical phenotypes. Disease Patient population Frequency (%) Associated Clinical Characteristics
More informationUnderstanding Your Blood Work Results
Understanding Your Blood Work Results Carlos Besses, MD, hd Hematology Department Hospital del Mar - IMIM, Barcelona Carlos Besses Disclosures Novartis Honorarium Speaker Shire Honorarium Speaker Galena
More information3. Pardanani A, et al. Leukemia 2009;23: Hedvat M, et al. Cancer Cell 2009;16:
A Phase / Study of NS-8, an Oral JAK Inhibitor, in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (ppv MF), or Post-Essential Thrombocythemia Myelofibrosis (pet MF) 8 Srdan
More informationRuben A. Mesa, MD & John Camoranio, MD Mayo Clinic
Arizona, USA Prognosis & MPN Management in 2013 Ruben A. Mesa, MD & John Camoranio, MD Mayo Clinic Arizona, USA Understanding MPN Therapy Options Prognosis and Goals (Mesa & Camoriano) Evolving Rx ET (Vannucchi)
More informationThe prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia
Received: 3 February 2017 Revised: 13 February 2017 Accepted: 14 February 2017 DOI: 10.1002/ajh.24689 RESEARCH ARTICLE The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin
More informationChronic Idiopathic Myelofibrosis (CIMF)
Chronic Idiopathic Myelofibrosis (CIMF) CIMF Synonyms Agnogenic myeloid metaplasia Myelosclerosis with myeloid metaplasia Chronic granulocytic-megakaryocytic myelosis CIMF Megakaryocytic proliferation
More informationDisclosures. Myeloproliferative Neoplasms: A Case-Based Approach. Objectives. Myeloproliferative Neoplasms. Myeloproliferative Neoplasms
Myeloproliferative Neoplasms: A Case-Based Approach Disclosures No conflicts of interests regarding the topic being presented Adam M. Miller, MD PGY-4 Resident Physician Department of Pathology and Laboratory
More informationChronic Myeloproliferative Disorders
1 Chronic Myeloproliferative Disorders 15th 9 April2015 Polycythemia vera Essential thrombocythemia Idiopathic primary myelofibrosis 2 Learning objectives To appreciate types of polycythaemia (erythrocytosis)
More informationNovel drugs in MPNs: Histone-Deacetylase Inhibitors
Novel drugs in MPNs: HistoneDeacetylase Inhibitors 1st Annual Florence MPN Meeting April 16, 2011 Guido Finazzi Chronic Myeloproliferative Neoplasm Unit Division of Hematology Ospedali Riuniti di Bergamo,
More informationUnderstanding how Jakafi (ruxolitinib) inhibits* overactive JAK pathway signaling
Understanding how Jakafi (ruxolitinib) inhibits* overactive JAK pathway signaling * Jakafi, a kinase inhibitor, inhibits and (Janus-associated kinases 1 and 2), which mediate the signaling of cytokines
More informationEssential thrombocythemia treatment algorithm 2018
Tefferi et al. (2018) 8:2 DOI 10.1038/s41408-017-0041-8 CURRENT TREATMENT ALGORITHM Essential thrombocythemia treatment algorithm 2018 Ayalew Tefferi 1, Alessandro M. Vannucchi 2 and Tiziano Barbui 3 Open
More informationEmerging diagnostic and risk stratification criteria
PV STATE OF MIND Polycythemia vera: Emerging diagnostic and risk stratification criteria Rami S. Komrokji, MD Moffitt Cancer Center, Tampa, Florida Disclosure These slides were developed by Incyte Corporation
More informationDiagnostic Molecular Pathology of Myeloid Neoplasms
Diagnostic Molecular Pathology of Myeloid Neoplasms Beirut, Lebanon Tuesday November 29, 2011: Pre-congress workshop Adam Bagg University of Pennsylvania Philadelphia, USA Myeloid neoplasms Myeloproliferative
More informationTargeted next-generation sequencing in blast phase myeloproliferative neoplasms
REGULAR ARTICLE Targeted next-generation sequencing in blast phase myeloproliferative neoplasms Terra L. Lasho, Mythri Mudireddy, Christy M. Finke, Curtis A. Hanson, Rhett P. Ketterling, Natasha Szuber,
More informationMyelodysplastic syndrome (MDS) & Myeloproliferative neoplasms
Myelodysplastic syndrome (MDS) & Myeloproliferative neoplasms Myelodysplastic syndrome (MDS) A multipotent stem cell that can differentiate into any of the myeloid lineage cells (RBCs, granulocytes, megakaryocytes)
More informationORIGINAL ARTICLE. A Tefferi 1, TL Lasho 1, J Huang 1, C Finke 1, RA Mesa 1,CYLi 2,WWu 3, CA Hanson 2 and A Pardanani 1
(28) 22, 756 76 & 28 Nature Publishing Group All rights reserved 887-6924/8 $3. www.nature.com/leu ORIGINAL ARTICLE, compared to either a higher allele burden or unmutated status, is associated with inferior
More informationBy Angela Gascoigne Haematology CNS Chesterfield Royal Hospital
By Angela Gascoigne Haematology CNS Chesterfield Royal Hospital Myeloproliferative Neoplasms Essential Thrombocythaemia Polycythaemia Vera Myelofibrosis Essential Thrombocythaemia (ET) Chronic condition
More informationPiper Jaffray Healthcare Conference
Piper Jaffray Healthcare Conference John Scarlett, M.D. President and CEO, Geron Corporation November 2018 Forward-Looking Statements Except for statements of historical fact, the statements contained
More informationHSCT for Myeloproliferative Disorders. Jane Apperley
HSCT for Myeloproliferative Disorders Jane Apperley Myeloproliferative disorders CML Polycythemia vera Essential thrombocythemia Primary myelofibrosis bcr-abl + bcr-abl - JAK2 (valine to phenylalanin an
More informationGuidelines for diagnosis and management of adult myeloproliferative neoplasms (PV, ET, PMF and HES)
Guidelines for diagnosis and management of adult myeloproliferative neoplasms (PV, ET, PMF and HES) Author: Dr N Butt, Consultant Haematologist On behalf of the Haematology CNG Written: July 2010 Reviewed:
More informationJune Ruxolitinib for the second-line treatment of myelofibrosis (IPSS intermediate LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW
LONDON CANCER NEWS DRUGS GROUP RAPID REVIEW Ruxolitinib for the second-line treatment of myelofibrosis (IPSS intermediate risk-1 or above) Ruxolitinib for the second-line treatment of myelofibrosis (IPSS
More informationUpdate in Myeloproliferative Neoplasms
Update in Myeloproliferative Neoplasms 2018 UPDATE IN HEMATOLOGIC MALIGNANCIES January 26, 2018 Daria Babushok, MD PhD Learning Objectives Philadelphia-chromosome negative MPNs 1. To review key changes
More informationJAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data
JAK2 inhibitors in the treatment of myeloproliferative neoplasms: rationale and clinical data Clin. Invest. (2011) 1(12), 1681 1693 The seminal discovery of the high prevalence of the JAK2-V617F mutation
More informationNew WHO Classification of Myeloproliferative Neoplasms
New WHO Classification of Myeloproliferative Neoplasms Hans Michael Kvasnicka Senckenberg Institute of Pathology, University of Frankfurt, Germany hans-michael.kvasnicka@kgu.de Principles and rationale
More informationUpdate on Myelodysplastic Syndromes and Myeloproliferative Neoplasms. Kaaren Reichard Mayo Clinic Rochester
Update on Myelodysplastic Syndromes and Myeloproliferative Neoplasms Kaaren Reichard Mayo Clinic Rochester Reichard.kaaren@mayo.edu Nothing to disclose Conflict of Interest Learning Objectives Present
More informationMYELOPROLIFERATIVE NEOPLASMS
9 : 2 MYELOPROLIFERATIVE NEOPLASMS Introduction William Dameshek in 1951 introduced the term Myeloproliferative disorders (MPD). This included polycythemia vera (PV), essential thrombocythemia (ET), primary
More information